Search
Iodipamide
go.drugbank.com/drugs/DB04711ApprovedWithdrawnIodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.
Categories: Compounds used in a research, industrial, or household settingLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Triflusal
go.drugbank.com/drugs/DB08814ApprovedWithdrawnUriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada. … Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative.
Pentetreotide
go.drugbank.com/drugs/DB12602ApprovedWithdrawnPentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.
Categories: Compounds used in a research, industrial, or household settingSepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.
Buclizine
go.drugbank.com/drugs/DB00354Approved[A178102] In addition to the above conditions, buclizine has been studied in the treatment of migraine attacks and in the treatment of nausea and vomiting during pregnancy. [A178105, A178108] … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.
Riociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III.
Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminateAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Lys-63-specific deubiquitinase BRCC36
go.drugbank.com/bio_entities/BE0009071TargetHumansMediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:19214193). … Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites
Synonyms: BRCA1-A complex subunit BRCC36, BRISC complex subunit BRCC36Gadoquatrane
go.drugbank.com/drugs/DB33282Approvedin the central nervous system and in the body. … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity